These positive effects have been attributed to the multifaceted anti-tumoral properties of IL-12, including Th1 maturation of CD8+ T cells and induction of anti-angiogenic mechanisms 9, 38, in combination with adaptive immune cell recruitment and cancer cell lysis induced by oHSV therapy 8, 39. The gene discussed is CD8A; the disease is cancer.